About Human Prostacyclin Receptor (PTGIR/IP Receptor) Stable Cell Line

Prostacyclin Receptor (PTGIR), also known as the IP receptor, is a Class A G protein-coupled receptor (GPCR) that serves as the primary receptor for prostacyclin (PGI₂), a biologically active prostanoid produced mainly by vascular endothelial cells. PTGIR plays a critical role in cardiovascular homeostasis by mediating the vasodilatory, anti-thrombotic, and anti-proliferative effects of prostacyclin. Upon activation by PGI₂ or synthetic prostacyclin analogs, PTGIR primarily couples to Gs proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels, which subsequently regulate vascular tone, platelet function, and cellular signaling pathways.

PTGIR is widely expressed in vascular smooth muscle cells, endothelial cells, platelets, cardiac tissues, and other organs involved in cardiovascular regulation. Activation of PTGIR promotes vasodilation, inhibits platelet aggregation, suppresses vascular smooth muscle proliferation, and contributes to protection against thrombosis and vascular injury. Dysregulation of prostacyclin signaling has been implicated in pulmonary arterial hypertension (PAH), cardiovascular disease, atherosclerosis, thrombosis, inflammation, and vascular remodeling disorders. As a result, PTGIR has become an important therapeutic target in cardiovascular medicine and pulmonary hypertension drug development.

eEnzyme's Human PTGIR Stable Cell Line provides a reliable and reproducible cellular platform for investigating prostacyclin receptor pharmacology and signaling mechanisms. The cell line enables quantitative assessment of prostacyclin analogs, agonists, antagonists, and novel receptor modulators through cAMP assays, reporter gene assays, and other GPCR functional screening platforms. Researchers can utilize this stable cell line for receptor characterization, potency determination, lead optimization, biosimilar evaluation, and high-throughput screening applications supporting cardiovascular and pulmonary disease research.

Applications of the PTGIR Stable Cell Line

• PTGIR receptor pharmacology studies
• Prostacyclin (PGI₂) signaling investigations
• Agonist and antagonist screening
• Pulmonary arterial hypertension (PAH) drug discovery
• Cardiovascular and vascular biology research
• Platelet function and thrombosis studies
• cAMP and GPCR functional assays
• High-throughput screening applications

Biological Significance of PTGIR

PTGIR is a key regulator of vascular function and cardiovascular health. Activation of the receptor by prostacyclin stimulates cAMP-dependent signaling pathways that promote vasodilation, inhibit platelet activation, and suppress vascular smooth muscle cell proliferation. These protective effects help maintain normal blood flow and reduce the risk of thrombosis and vascular remodeling. Therapeutic activation of PTGIR has proven highly effective in the treatment of pulmonary arterial hypertension, with several prostacyclin analogs and IP receptor agonists approved for clinical use. In addition to its cardiovascular functions, PTGIR signaling also contributes to inflammatory regulation, tissue protection, and endothelial homeostasis. Because of its central role in vascular biology and proven clinical relevance, PTGIR remains an important target for cardiovascular research, pulmonary hypertension therapeutics, and GPCR-focused drug discovery programs. The PTGIR Stable Cell Line provides a valuable tool for studying prostacyclin receptor biology and advancing the development of next-generation cardiovascular therapies.